Search filters

List of works by Francis Giles

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

scientific article

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

scientific article

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes

scientific article

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes

scientific article published in August 2002

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

scientific article

A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia

scientific article

A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies

scientific article published in December 2008

A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

scientific article published on January 2007

A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

scientific article published in February 2007

A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry

scientific article

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

scientific article published in March 2003

A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens

scientific article

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

scientific article published on July 2005

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

scientific article

Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies

scientific article

Advances in the therapy of chronic idiopathic myelofibrosis

scientific article published on September 2006

Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure

scientific article

An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation

scientific article published on 26 December 2007

Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase

scientific article published in October 2003

Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?

scientific article published on December 2006

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

scientific article

C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome

scientific article published in April 2004

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

scientific article published in August 2017

Challenges in Opening and Enrolling Patients in Clinical Trials

scientific article published in January 2017

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

scientific article

Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase

scientific article published in November 2003

Circulating CD33 and its clinical value in acute leukemia

scientific article published on April 2010

Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

scientific article

Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies

scientific article

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

scientific article

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

scientific article published on 14 March 2006

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

scientific article

Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment

scientific article

Current status of therapy for chronic myeloid leukemia: a review of drug development

scientific article published on June 2008

Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

scientific article published on May 2012

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

scientific article published on 12 September 2002

Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

scientific article

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

scientific article

Effects of Clinically Relevant MPL Mutations in the Transmembrane Domain Revealed at the Atomic Level through Computational Modeling ⬇️

scientific article published on August 17, 2011

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in September 2003

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

scientific article published on 31 October 2002

Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia ⬇️

scientific article published on January 9, 2012

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

scientific article published in June 2003

Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia

scientific article published in March 2008

Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation

scientific article published on 20 October 2009

Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

scientific article

Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy

scientific article published in July 2003

Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies

scientific article published in September 2004

Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome

scientific article published in January 2002

GSK-3 inhibition overcomes chemoresistance in human breast cancer

scientific article published on 14 July 2016

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

scientific article published in March 2003

High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia

scientific article published on 24 December 2003

Higher detection rate of JAK2 mutation using plasma.

scientific article

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

scientific article published on 2 September 2004

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

scientific article published on 29 August 2002

Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia

scientific article published in July 2004

Important therapeutic targets in chronic myelogenous leukemia

scientific article published on February 2007

Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia

scientific article

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

scientific article published in February 2004

Investigational strategies in chronic myelogenous leukemia

scientific article published in June 2004

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms ⬇️

scientific article (publication date: 13 August 2010)

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

scientific article

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

scientific article

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome

scientific article published on January 2003

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

scientific article published in March 2006

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

scientific article

Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.

scientific article published on March 2007

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

scientific article published in November 2004

Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations

scientific article published in April 2009

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

scientific article

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

scientific article

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

scholarly article by Robert J Kreitman et al published August 2018 in Leukemia

Myelodysplastic syndrome: from morphology to biology.

scientific article published on May 2004

New agents in acute myeloid leukemia and other myeloid disorders

scientific article published on February 2004

New agents in chronic myelogenous leukemia.

scientific article published on October 2003

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

scientific article published on December 2006

New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance

scientific article published on January 2007

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

scientific article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

scientific article

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

scientific article (publication date: 15 June 2006)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.

scientific article published on 21 September 2009

Nodal Signaling as a Developmental Therapeutics Target in Oncology

scientific article published on May 2017

Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.

scientific article published on March 2007

Novel therapies for myelofibrosis

scientific article

Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies

scientific article published on April 2004

Outcome of patients with acute myelogenous leukemia after second salvage therapy

scientific article published on August 2005

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

scientific article published on June 2006

Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies

scientific article

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

scientific article

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

scientific article

Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse

scientific article published on 26 August 2009

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

scientific article published in March 2003

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

scientific article

Phase I study of bortezomib in refractory or relapsed acute leukemias

scientific article published in May 2004

Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia

scientific article published on November 2005

Phase I study of oral topotecan in hematological malignancies ⬇️

scientific article published on September 15, 2003

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

scientific article published in January 2007

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

scientific article

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

scientific article

Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

scientific article published in May 2003

Pregnancy among patients with chronic myeloid leukemia treated with imatinib

scientific article published on 30 January 2006

Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System

scientific article published in June 2007

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

scientific article

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

scientific article

Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome

scientific article

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

scientific article published in January 2003

Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer

scientific article published on 9 July 2016

Recent advances in the diagnosis and therapy of Richter's syndrome

scientific article

Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia ⬇️

scientific article published on October 23, 2003

Repurposing metformin for cancer treatment: current clinical studies

scientific article

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha

scientific article published on 13 March 2003

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

scientific article

Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome

scientific article published in April 2004

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

scientific article published in June 2003

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

scientific article published in September 2003

Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy

scientific article published in August 2005

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib

scientific article published on 18 May 2017

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

scientific article

Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

scientific article

Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications

scientific article published in July 2003

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

scientific article

Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience

scientific article published in May 2005

Targeting novel signaling pathways for resistant acute myeloid leukemia

scientific article published on 05 December 2014

Targeting sarcomas: novel biological agents and future perspectives

scientific article published on October 2009

The Pim kinases: new targets for drug development

scientific article published on December 2011

The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy

scientific article published in July 2005

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

scientific article published on 21 April 2009

The incidence and impact of thrombocytopenia in myelodysplastic syndromes

scientific article published in May 2007

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase

scientific article

Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

scientific article

Troxacitabine in leukemia

scientific article published on October 2006

Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease

scientific article

Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy

scientific article published in October 2002

Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes

scientific article

Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? ⬇️

scientific article published on May 20, 2013

Paulina is supported by:

About Paulina

Help